Form 4: BioAge Labs Director Receives Stock Option Grant

Director Patrick G. Enright was granted 22,000 stock options in BioAge Labs, Inc. as part of standard equity compensation.

Summary

• Director Patrick G. Enright received a grant of 22,000 stock options on June 10, 2026.
• The options have an exercise price of $15.48 per share.
• The options are set to expire on June 9, 2036.
• The grant is subject to a vesting schedule tied to the next annual meeting or the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $15.48 exercise price.

Future Outlook

The options vest on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with typical compensation packages for directors in mid-cap clinical-stage biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options upon the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

BioAge Labs, BIOA, Form 4, Insider Trading, Stock Options, Director Compensation